Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06686368

Comparative Efficacy Study to Demonstrate the Non-inferiority of I-DROP® MGD Versus 2 Competitor Eye Drops in Managing Evaporative Dry Eye

A Pilot Comparative study between I-DROP MGD vs two commercially available lubricant eye drops for the management of evaporative dry eye

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

About this study

Pilot, randomized, double-blind, prospective, non-inferiority study to demonstrate the safety and efficacy of I-DROP MGD vs two commercially available preservative-free lubricant eye drops for the management of evaporative dry eye

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Is at least 18 years of age and has full legal capacity to volunteer.
  • Has read and signed an information consent form.
  • Is willing and able to follow instructions and maintain the appointment schedule.
  • Has dry eye disease as per the TFOS DEWS II definition with a clear moderate to severe evaporative Dry Eye:
  • OSDI ≥ 13
  • And TBUT < 10 seconds
  • And >5 spots of corneal fluorescein staining OR > 9 conjunctival spots
  • Meibomian Gland score of 1 or higher using NEI grading criteria.

Exclusion criteria

  • Is participating in any concurrent clinical or research study.
  • Is wears contact lenses.
  • Is using any systemic medications that could impact the aqueous tear layer, including antihistamines, vitamin A analogues, phenothiazines, anti-anxiety drugs, antidepressants, and other medications with anticholinergic activity.
  • Has undergone eye surgery involving the cornea or conjunctiva.
  • Aqueous deficient DED patients.
  • Is currently or has used any of the study drops in the last 3 months.
  • Has any known allergy or intolerance to any of the study drops.
  • Has any known active ocular disease such as allergies and/or infection or any ocular disease that in the opinion of the investigator may affect a study outcome variable
  • Has a systemic condition that in the opinion of the investigator may affect a study outcome variable (e.g. uncontrolled autoimmune disease or uncontrolled immunodeficiency disease).
  • Has known sensitivity to sodium fluorescein.
  • Is pregnant, lactating or planning a pregnancy at the time of enrolment?
  • Unwilling to stop using their habitual artificial tears for the study.
  • Has been fitted with punctal plugs within 30 days before the study screening visit.
  • Contact lens users can still qualify for the study, however, participants should restrain their contact lens use to a very minimum during the study duration.

Treatment and study plan

I-DROP MGD

Device

All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30

Theloze Duo

Device

All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30

Systane Complete PF

Device

All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30

Primary outcomes

  1. Fluorescein Tear Break-Up Time (FTBUT) in seconds

    Time frame: Day 1 - 30 minutes post installation

    The primary outcome of the study is FBUT at 30 minutes post-installation

Secondary outcomes

  1. Fluorescein Tear Break-Up Time (FTBUT) in seconds

    Time frame: Day 7 - day 28

    One of the secondary endpoints is FTBUT at day 7 and day 28

  2. Tear Meniscus Height (TMH) in milimiters

    Time frame: Day 1 - Day 7 - day 28

    One of the secondary endpoints is TMH at day 1 (30 minutes post-installation), 7 and day 28

  3. Osmolarity in mOsm/L

    Time frame: Day 1 - Day 7 - day 28

    One of the secondary endpoints is osmolarity at day 1 (30 minutes post-installation), 7 and day 28

  4. Number of Corneal and Conjunctival spots

    Time frame: Day 7 - day 28

    One of the secondary endpoints is Corneal and conjunctival spots at day 7 and day 28

  5. Ocular Surface and Disease Index (OSDI) score

    Time frame: Day 7 - day 28

    One of the secondary endpoints is OSDI score at day 7 and day 28

Study contacts

Contact information is provided by the study sponsor or research team.

Karim Fahmy, Ph.D.

CONTACT

[email protected]

1-800-463-1008

Sponsors and collaborators

Lead sponsor

I-MED Pharma

Industry

Registry information

Official study title

Comparative Efficacy of I-DROP®MGD Versus Competing Eye Drops in Managing Evaporative Dry Eye: A Pilot Randomized Controlled Trial

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Nov 13, 2024
Registry last updated
Nov 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.